This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Elijah Saunders; Matthew R. Weir; B. Wayne Kong; John Hollifield; James Gray; Victor Vertes; James R. Sowers; Michael B. Zemel; Charles Curry; James Schoenberger; Jackson T. Wright; Walter Kirkendall; Edward C. Conradi; Patricia Jenkins; Barry McLean; Barry Massie; Gerald Berenson; Walter Flamenbaum

Arch Intern Med. 1990;150(8):1707-1713.

Abstract
A double-blind, positively controlled, forced dose titration study comparing the efficacy and safety of atenolol, captopril, and verapamil sustained release as single agents in the treatment of black patients with mild to moderate hypertension (diastolic blood pressure, 95 to 114 mm Hg) was conducted. A total of 394 patients were randomized to one of the three therapies. Mean blood pressures during a 2- to 4-week placebo treatment period (baseline) ranged from 100.4 to 100.7 mm Hg diastolic and 151.7 to 152.5 mm Hg systolic for the three groups. Of the patients, 355 (of whom 345 had assessable data) completed the first treatment period, which consisted of therapy with either 50 mg/d of atenolol, 25 mg every 12 hours of captopril, or 240 mg/d of verapamil sustained release. During the second 4-week treatment period, which 319 patients completed (307 assessable), half of the patients had their antihypertensive medication increased and the other half continued the same dose. Goal blood pressure was defined as a supine diastolic pressure of less than 90 mm Hg or a 10—mm Hg or greater drop in supine diastolic blood pressure from pretreatment levels. Atenolol, captopril, and verapamil sustained release therapy was associated with goal blood pressure achievement during the first treatment period 55.1%, 43.8%, and 65.2% of the time, respectively, and during the second treatment period 59.6%, 57.1%, and 73.0% of the time. Side effects were minimal and comparable for all three drugs.

(Arch Intern Med. 1990;150:1707-1713)

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Racial Analysis of Patients With Myocardial Infarction Complicated by Heart Failure and/or Left Ventricular Dysfunction Treated With Valsartan, Captopril, or Both
Prisant et al.
J Am Coll Cardiol 2008;51:1865-1871.
ABSTRACT | FULL TEXT  

Management of hypertension in ethnic minorities
Khan and Beevers
Heart 2005;91:1105-1109.
FULL TEXT  

Comparison of Monotherapy with Irbesartan 150 mg or Amlodipine 5 mg for Treatment of Mild-to-Moderate Hypertension
Neutel et al.
Journal of Renin-Angiotensin-Aldosterone System 2005;6:84-89.
ABSTRACT  

Outcomes in Hypertensive Black and Nonblack Patients Treated With Chlorthalidone, Amlodipine, and Lisinopril
Wright et al.
JAMA 2005;293:1595-1608.
ABSTRACT | FULL TEXT  

Heart failure--the importance of ethnicity
Sosin et al.
Eur J Heart Fail 2004;6:831-843.
ABSTRACT | FULL TEXT  

Systematic Review: Antihypertensive Drug Therapy in Black Patients
Brewster et al.
ANN INTERN MED 2004;141:614-627.
ABSTRACT | FULL TEXT  

Determinants of Blood Pressure Response to Quinapril in Black and White Hypertensive Patients: The Quinapril Titration Interval Management Evaluation Trial
Mokwe et al.
Hypertension 2004;43:1202-1207.
ABSTRACT | FULL TEXT  

Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure
Chobanian et al.
Hypertension 2003;42:1206-1252.
ABSTRACT | FULL TEXT  

`Size is not everything`: the Antihypertensive and Lipid-Lowering treatment to prevent Heart Attack Trial (ALLHAT): The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomised to angiotensin-converting enzyme inhibitor or calcium channel blocker versus diuretic. The Antihypertensive and Lipid-Lowering treatment to prevent Heart Attack Trial (ALLHAT)
Mcinnes
British Journal of Diabetes & Vascular Disease 2003;3:263-267.
ABSTRACT  

Efficacy and tolerability of eplerenone and losartan in hypertensive black and white patients
Flack et al.
J Am Coll Cardiol 2003;41:1148-1155.
ABSTRACT | FULL TEXT  

Management of High Blood Pressure in African Americans: Consensus Statement of the Hypertension in African Americans Working Group of the International Society on Hypertension in Blacks
Douglas et al.
Arch Intern Med 2003;163:525-541.
FULL TEXT  

Initial Treatment of Hypertension
August
NEJM 2003;348:610-617.
FULL TEXT  

Major Outcomes in High-Risk Hypertensive Patients Randomized to Angiotensin-Converting Enzyme Inhibitor or Calcium Channel Blocker vs Diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)
The ALLHAT Officers and Coordinators for the ALLHA
JAMA 2002;288:2981-2997.
ABSTRACT | FULL TEXT  

Race and Responsiveness to Drugs for Heart Failure
Bovet et al.
NEJM 2001;345:766-768.
FULL TEXT  

Lesser Response to Angiotensin-Converting-Enzyme Inhibitor Therapy in Black as Compared with White Patients with Left Ventricular Dysfunction
Exner et al.
NEJM 2001;344:1351-1357.
ABSTRACT | FULL TEXT  

Angiotensin II Receptor Blockers: Equal or Preferred Substitutes for ACE Inhibitors?
Grossman et al.
Arch Intern Med 2000;160:1905-1911.
FULL TEXT  

The management of hypertensive disease in Black patients
Gibbs et al.
QJM 1999;92:187-192.
ABSTRACT | FULL TEXT  

Comparison of the Efficacy of Dihydropyridine Calcium Channel Blockers in African American Patients With Hypertension
Hall et al.
Arch Intern Med 1998;158:2029-2034.
ABSTRACT | FULL TEXT  

Influence of Race and Dietary Salt on the Antihypertensive Efficacy of an Angiotensin-Converting Enzyme Inhibitor or a Calcium Channel Antagonist in Salt-Sensitive Hypertensives
Weir et al.
Hypertension 1998;31:1088-1096.
ABSTRACT | FULL TEXT  

Effect of Calcium Channel or ß-Blockade on the Progression of Diabetic Nephropathy in African Americans
Bakris et al.
Hypertension 1997;29:744-750.
ABSTRACT | FULL TEXT  

Efficacy and Tolerance of Antihypertensive Treatment in Men and Women With Stage 1 Diastolic Hypertension: Results of the Treatment of Mild Hypertension Study
Lewis et al.
Arch Intern Med 1996;156:377-385.
ABSTRACT  

Differing Mechanisms of Action of Angiotensin-Converting Enzyme Inhibition in Black and White Hypertensive Patients
Weir et al.
Hypertension 1995;26:124-130.
ABSTRACT | FULL TEXT  

Selected Factors That Influence Responses to Antihypertensives: Choosing Therapy for the Uncomplicated Patient
Carter et al.
Arch Fam Med 1994;3:528-535.
ABSTRACT  

Angiotensin-Converting Enzyme Inhibitors in Hypertension: A Dozen Years of Experience
Materson and Preston
Arch Intern Med 1994;154:513-523.
ABSTRACT  

Single-Drug Therapy for Hypertension in Men -- A Comparison of Six Antihypertensive Agents with Placebo
Materson et al.
NEJM 1993;328:914-921.
ABSTRACT | FULL TEXT  

Antihypertensive Therapy -- Efficacy and Quality of Life
Oparil
NEJM 1993;328:959-961.
FULL TEXT  

Can We Prevent End-Stage Renal Disease due to Hypertension or to Diabetes Mellitus?
Luke
JAMA 1992;268:3119-3120.
ABSTRACT  

Calcium Antagonists in Elderly and Black Hypertensive Patients: Therapeutic Controversies
Zing et al.
Arch Intern Med 1991;151:2154-2162.
ABSTRACT  

A Randomized Controlled Trial of the Effects of Three Antihypertensive Agents on Blood Pressure Control and Quality of Life in Older Women
Applegate et al.
Arch Intern Med 1991;151:1817-1823.
ABSTRACT  

Hypertensive Black Men and Women
Croog et al.
Arch Intern Med 1990;150:1733-1741.
ABSTRACT